BioCatalystFeed / Readout calendar / FDA decisions / Drugs / Disease areas / Companies / Months
IRON upcoming catalysts
Disc Medicine, Inc: 0 upcoming industry Phase 2/3 trial readout(s) in the next 90 days (0 Phase 3), 0 upcoming FDA decision event(s), and in the last 12 months 2 readout(s) and 1 FDA event(s). Subscribe to IRON (.ics).
Upcoming FDA decision events
| Date | Event | Status | Company | Drug | Source |
|---|
| No upcoming PDUFA date or AdCom found. |
Upcoming trial readouts
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| No trials in this window. |
FDA decision events, last 12 months
Trial readouts, last 12 months
| Readout | Phase | Sponsor | Trial | Conditions | Status | Enrollment |
|---|
| 2026-10 est. | P2 | Disc Medicine, Inc IRON | NCT07368972 Study of DISC-0974-201 in Participants With IBD and Anemia | Inflammatory Bowel Disease (IBD); Anemia; Inflammatory Bowel Disease (IBD); Anemia | recruiting | 21 |
| 2026-09-08 | P3 | Disc Medicine, Inc IRON | NCT06910358 Study of Bitopertin in Participants With EPP or XLP (APOLLO) | Erythropoietic Protoporphyria (EPP); X-Linked Protoporphyria (XLP) | completed | 183 |
Readout = ClinicalTrials.gov primary completion date (sponsor-reported; est. dates often slip; top-line
results usually follow weeks to months later). FDA events: PDUFA dates are extracted from company 8-K filings (SEC EDGAR) and are
company-disclosed and UNVERIFIED - read the filing; AdCom meetings come from Federal Register notices; approvals from Drugs@FDA
(openFDA); complete response letters from openFDA (published with a lag). Tickers are matched by name with a confidence score.
Generated 2026-11-18T17:57:33Z. Same data: bcf readouts search, bcf fda-decisions search, MCP
readout_calendar / fda_decisions. Not investment advice.